Mirae Asset Horizons S&P Crude Oil Futures Enhanced ER ETF (03097.HK) Rises 3.61%, Intraday Swing of 12.98%
NewTimeSpace News: As of 10:16 on June 11, Mirae Asset Horizons S&P Crude Oil Futures Enhanced ER ETF (03097.HK) stood at HKD 8.900, up 3.61%. The ETF opened at HKD 7.785, recorded a high of HKD 8.900, representing an intraday swing of 12.98%, with 132,000 shares traded, a turnover of approximately HKD 1.1733 million, an average price of HKD 8.889, a latest Net Asset Value (NAV) of HKD 8.585, a premium rate of 1.46%, and total Assets Under Management (AUM) of approximately HKD 116 million.
Mirae Asset Horizons S&P Crude Oil Futures Enhanced ER ETF (03097.HK) closely tracks the S&P GSCI Crude Oil Enhanced Extra Return Index. The index captures crude oil price movements by investing in crude oil futures contracts and employs enhancement strategies to optimize roll yields, reflecting price changes and term structure dynamics in the international crude oil market.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- Innogen-B (02591.HK): Two Contract Manufacturing Sites for Isupaglutide α Injection Obtain PIC/S GMP Certificates
- CSPC PHARMA(01093.HK): Phase Ib/II Clinical Trial of SYS6090 Injection for Colorectal Cancer Initiated at First Study Centre in China
- Ascletis-B (01672.HK): Oral Small-molecule GLP-1 ASC30 Initiates Global Phase III Clinical Trials; First-in-class Triple-target FDC Achieves 15.2% Weight Loss in Preclinical Studies
- WUXI APPTEC(02359.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 11.08 billion, YoY increase of 33.7%
- SH PHARMA(02607.HK): Omeprazole Sodium Bicarbonate for Oral Suspension (I) Approved for Production